Efficacy of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: A Real-life Experience and Outcome from a Tertiary Care Centre

Samia Yasmeen¹, Farah Arshad², Sabah Shaukat³, Farhana Badar⁴, Syed Ather Saeed Kazmi⁵, Usman Ahmad⁶

¹Department of Medical Oncology, Prince Faisal Cancer Center, Buraidah, Kingdom of Saudi Arabia, ²Department of Internal Medicine, Shalamar Institute of Health Sciences, Lahore, Pakistan, ³Department of Internal Medicine, Furness General Hospital, University Hospitals of Morecambe Trust, Barrow, United Kingdom, ⁴Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan, ⁵King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia, ⁶Rowen House, Pinderfields General Hospital, Wakefield, United Kingdom

Received: 31 May 2021/Accepted: 19 June 2021

Abstract

Introduction: To report response rates, progression-free survival (PFS) and overall survival (OS) in patients with advanced pancreatic cancer treated with different available chemotherapeutic regimens over 10 years.

Materials and Methods: This is a retrospective observational study. All patients with locally advanced and metastatic pancreatic cancer (MPC) at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, from January 2008 to December 2017 were studied. Data were collected from the hospital information system. The characteristics and outcomes of all the patients were analysed. PFS and OS were also estimated. Kaplan–Meier curves and log-rank test were applied, and SPSS version 20 was used for data analysis.

Results: Eighty-seven subjects with a median age of 56 years (range 21–76) were included. Sixty-two (71%) subjects were male. The most common tumour location was the head of the pancreas in 46 (53%) of all the subjects. Sixty-three (72%) subjects had elevated carbohydrate antigen-19.9 values. About 47 (54%) subjects had locally advanced pancreatic cancer (LAPC), and 40 (46%) subjects had MPC. Chemotherapy regimens used were FOLFIRINOX in 23 (26%), gemcitabine (GEM) based in 66 (65%) and capecitabine (CAP) based in 8 (9%) of the subjects. One (1%) subject had a complete response, 12 (14%) had a partial response, 10 (11%) had stable disease and 59 (68%) of the subjects had progressive disease. The objective response rate (ORR) was 15% and the disease control rate (DCR) was 26%. In MPC, the ORR was 10%, DCR was 18% and tumour progression was documented in 72% of the patients, while in LAPC, the ORR was 19.1, DCR 34% and tumour progression was seen in 72% of the patients, while in LAPC, the ORR was 19.1, DCR 34% and tumour progression was documented in 64% of the patients, respectively. The FOLFIRINOX chemotherapy regimen had better ORR, DCR and lesser number of progressions as compared to GEM- and CAP-based chemotherapy regimens. The median PFS of the whole group was 32 weeks, and the median OS was 54 weeks. The PFS was significantly higher for LAPC (39 weeks) as compared to the MPC group (25 weeks).
Introduction

Pancreatic ductal adenocarcinoma is one of the most typical gastrointestinal tract malignancies associated with dismal prognosis and an increasing impact on cancer-related mortality and one of the top five causes of cancer death worldwide despite being only the 11th most common cancer overall.\textsuperscript{[1-3]} 

Pancreatic cancer is clinically classified into three stages: Resectable, locally advanced and metastatic disease. The treatment strategy differs by the clinical stage, and it is important to determine the clinical stage in each pancreatic cancer patient to select the most appropriate treatment method.\textsuperscript{[4]}

It usually arises in elderly patients with a mean age at onset of 71 years for men and 75 years for women with roughly equal incidence for both sexes. The clinical course of pancreatic cancer usually is aggressive, with a high symptom burden and potential for a substantial deterioration in the quality of life. The red flag symptoms prompting diagnosis appear only once the disease has already progressed or metastasised; thus, only 10-20% of pancreatic cancers are resectable at the time of presentation.\textsuperscript{[5-7]}

The majority of patients present with advanced pancreatic cancers (locally advanced pancreatic cancer [LAPC] or metastatic pancreatic cancer [MPC]) have a very poor prognosis. The median overall survival (OS) is estimated to be 3-8 months. Moreover, the 5-year survival is around 1-3%, and the median life expectancy is approximately one year with current treatments.\textsuperscript{[6,8]}

A few years back, the only chemotherapy shown to provide a modest survival benefit had been gemcitabine (GEM), which improved median OS from 4.4 to 5.6 months compared to fluorouracil in a Phase III study.\textsuperscript{[9]} Attempts at improving survival with the combination of GEM and a variety of cytotoxic and molecularly targeted agents have failed to provide substantial additional benefit apart from the addition of erlotinib to GEM which was the only combination to provide a modest additional survival benefit of 6% at 1 year, resulting in an FDA approval for this agent.\textsuperscript{[1,10-12]}

In May 2011, Conroy et al. published the trial results on FOLFIRINOX as the first regimen to improve the median OS of patients with MPC beyond 10 months. This landmark trial was based on results of the initial Phase-II trial by Conroy et al. in 2005, which confirmed the efficacy of FOLFIRINOX with promising response rates and a good safety profile.\textsuperscript{[13-15]}

This study analysed the response rates in patients with advanced pancreatic cancer treated with different available chemotherapeutic regimens over 10 years. Furthermore, progression-free survival (PFS) and OS were calculated.

Methods

This retrospective study was done in a tertiary-level cancer hospital, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. A total of 104 patients were registered with a proven diagnosis of advanced pancreatic cancer (both LAPC and MPC) from January
2008 to December 2017. Inclusion criteria were histopathological diagnosis of advanced pancreatic cancer, age above 18 years and receipt of chemotherapy. Patients lost to follow-up before treatment completion were excluded from the analysis because their survival intervals were not available. The study protocols were reviewed by the Institutional Review Board of Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, and exemption was taken for informed consent as no direct interaction with patients was involved (EX-17-02-17-15).

The cancer diagnosis was made according to standard guidelines. Patient characteristics such as age, gender, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), pancreatic tumour location, the extent of disease, level of carbohydrate antigen (CA) - 19.9 and computed tomography scan results (before and after treatment) were analysed. Types of chemotherapy regimen were also recorded. The objective tumour responses included complete response (CR), partial response (PR), progressive disease (PD) and stable disease (SD). The objective response rate (ORR) was defined as the ratio between the number of patients achieving objective response (complete or PR) and the total number of patients in the study regardless of the number of patients that underwent disease response evaluation. Likewise, disease control rate (DCR) was defined as the ratio between the number of patients achieving disease control (CR, PR and SD) and the total number of patients in the study, regardless of the number of patients that underwent disease response evaluation. All of these evaluations were done using the standard RECIST criteria.

PFS was defined as the duration from the start of treatment to disease progression or death, whichever occurred first. OS was defined as the time interval from enrolment of the patient in the hospital to death from any cause or to last clinical follow-up.

Distributions were determined as frequencies and percentages for categorical variables. For continuous variables, mean, median, standard deviation and range were computed. The primary efficacy variable was OS, and the secondary endpoints of the study were tumour response and PFS.

Log-rank test and Kaplan-Meier estimations were performed for both PFS and OS. Response rates were calculated. Chi-square and Fisher exact tests, when suitable, were used to compare qualitative data. The difference was assumed to be significant when \( P \leq 0.05 \) and all tests were two sided. The analysis was conducted using SPSS version 20.

Results

Eighty-seven patients met the inclusion criteria and were included in the analysis. Among the 87 subjects included in the analysis, 62 (71%) subjects were male, and 25 (29%) were female. The median age was 56 ± 12.03 years (range 21–76 years). The ECOG-PS was 0, 1 and 2 in 24 (28%), 50 (57%) and 13 (15%) subjects, respectively. The most common tumour location was the head of the pancreas in 46 (53%) subjects. Twenty-four (28%) subjects had normal CA – 19.9 values and it was elevated in 63 (72%) subjects. Forty-seven (54%) subjects had LAPC, and 40 (46%) subjects had MPC. Chemotherapy regimens used were FOLFIRINOX in 23 (26%), GEM based in 66 (65%) and capecitabine (CAP) based in 8 (9%) of the subjects [Table 1].

One (1%) subject had a CR, 12 (14%) had a PR, 10 (11%) had SD and 59 (68%) of the subjects had PD. The ORR was 15%, and the DCR was 26%. In contrast, the response could not be evaluated in 5 (6%) of the subjects due to various reasons, including complications during treatment leading to referral to best supportive care or death. In MPC, the ORR was 10%, DCR was 18% and tumour progression was seen in 72% of the subjects, while in LAPC, the ORR was 19.1, DCR 34% and
tumour progression was documented in 64% of the subjects, respectively [Table 2].

The tumour responses according to chemotherapy regimens are shown in Table 2, which demonstrates that 5-fluorouracil (5-FU)-based (FOLFIRINOX) chemotherapy regimen had better ORR, DCR as compared to GEM-based and CAP-based chemotherapy regimens. Furthermore, fewer subjects progressed in the FOLFIRINOX regimen as compared to other regimens. However, due to the unequal distribution of sample size, further statistical analysis for significance, could not be possible [Table 2].

The median PFS of the whole group was 32 weeks, and the median OS was 54 weeks. The PFS was significantly higher for LAPC (39 weeks) as compared to the MPC group (25 weeks) \( (P = 0.028) \) [Figure 1a]. However, there was no statistically significant difference between OS of these two groups (66 weeks for LAPC vs. 49 weeks MPC, respectively, \( P = 0.451 \) [Figure 1b].

Three subjects had successful surgical resection (Whipple), and two subjects had R1 resection. Unfortunately, all of these three subjects passed away within a year.

In addition, PFS was significantly higher with 5-FU-based chemotherapy regimen (FOLFIRINOX) as compared to the other two chemotherapy regimens (101 weeks vs. 31 weeks vs. 19 weeks for 5-FU-, GEM- and CAP-based therapy, respectively, with \( P = 0.001 \) [Figure 2a]. Regarding OS, there was no statistically significant difference among all chemotherapy regimen groups (65 weeks vs. 63 weeks vs. 14 weeks for 5-FU-, GEM- and CAP-based chemotherapy regimens, respectively, \( P = 0.267 \) [Figure 2b].

Discussion

The treatment for MPC is chemotherapy only, whereas, in LAPC, chemotherapy and radiotherapy have been employed to improve response rates and make them resectable in <5% of cases.\(^{13}\) The purpose of this study was to assess the outcome of locally advanced and metastatic pancreatic cancer in the local population. The results of this study are consistent with the investigations conducted in the West and the South Asian region.

In this study, 87 subjects were analysed, of which 62 (71%) were male. This is not in line with the findings from other investigators.\(^{18,19}\) This disparity in gender distribution could be secondary to the regional culture or that the incidence of pancreatic cancer is different in this part of the world. The median age of the cohort was 56 years, which is not in broad agreement with the results from other international studies as they show a trend toward more advanced age.\(^{18,19}\) The exact reason for the earlier onset of disease in the present study

---

**Table 1: This table shows the baseline characteristics and chemotherapy regimens**

| Characteristics           | Category    | Number (%) |
|---------------------------|-------------|------------|
| Age (years)               | 56±12.03 (median)          |
| Gender                    | Male        | 62 (71)    |
|                           | Female      | 25 (29)    |
| ECOG-PS                   | 0           | 24 (28)    |
|                           | 1           | 50 (57)    |
|                           | 2           | 13 (15)    |
| Pancreatic tumour location | Head        | 46 (53)    |
|                           | Body        | 10 (12)    |
|                           | Tail        | 2 (2)      |
|                           | Neck        | 3 (3)      |
|                           | Uncinate    | 2 (2)      |
|                           | Periampullary| 6 (7)    |
|                           | Others      | 18 (21)    |
| CA 19.9 (units/ml)        | Normal      |            |
|                           | Low <59×ULN | 35 (40)    |
|                           | Elevated ≥59×ULN | 28 (32)   |
| Extent of disease         | Locally advanced | 47 (54)  |
|                           | Metastatic  | 40 (46)    |
| Chemotherapy regimens     | FOLFIRINOX based | 23 (26)  |
|                           | GEM based   | 56 (65)    |
|                           | CAP based   | 8 (9)      |

ECOG-PS: Eastern Cooperative Oncology Group-Performance status, ULN: Upper limit of normal, 5-FU: 5-fluorouracil, GEM: Gemcitabine, CAP: Capecitabine
is beyond the scope of this paper. However, it could be possible that elderly subjects were not well represented as they were too frail to receive chemotherapy.

Most of the patient had ECOG-PS 1, and 47 (54%) had LAPC, and 40 (46%) had MPC. Interestingly, most of the subjects had GEM 66 (65%), while only 23 (26%) subjects went on to have FOLFIRINOX. The reasons for this could be the patient’s choice, physician’s recommendation due to patient’s logistics and risk of toxicities that might have affected the chemotherapy choice. Furthermore, the need for the PICC line flush required every

**Table 2: This table summarises the tumour responses based on chemotherapy regimens**

| Characteristics | Category       | 5-FU-based chemotherapy (n=23) (%) | Gemcitabine-based chemotherapy (n=56) (%) | Capecitabine-based chemotherapy (n=8) (%) |
|-----------------|----------------|-----------------------------------|-------------------------------------------|------------------------------------------|
| Tumour response | CR             | 0 (0)                             | 1 (2)                                     | 0 (0)                                    |
|                 | PR             | 7 (31)                            | 5 (9)                                     | 0 (0)                                    |
|                 | SD             | 4 (17)                            | 6 (11)                                    | 0 (0)                                    |
|                 | PD             | 11 (48)                           | 42 (75)                                   | 6 (75)                                   |
|                 | Could not be assessed | 1 (4)                           | 2 (3)                                     | 2 (25)                                   |
| ORR             | Overall        | 7 (31)                            | 6 (11)                                    | 0 (0)                                    |
|                 | Locally advanced | 5 (72)                       | 4 (67)                                    | 0 (0)                                    |
|                 | Metastatic     | 2 (28)                            | 2 (33)                                    | 0 (0)                                    |
| DCR             | Overall        | 11 (48)                           | 12 (22)                                   | 0 (0)                                    |
|                 | Locally advanced | 8 (73)                       | 8 (67)                                    | 0 (0)                                    |
|                 | Metastatic     | 3 (27)                            | 4 (33)                                    | 0 (0%)                                   |
| Tumour progression | Overall  | 11 (48)                           | 42 (75)                                   | 6 (75)                                   |
|                 | Locally advanced | 7 (64)                       | 21 (50)                                   | 2 (33)                                   |
|                 | Metastatic     | 4 (36)                            | 21 (50)                                   | 4 (66)                                   |

CR: Complete response, PR: Partial response, SD: Stable disease, PD: Progressive disease, 5-FU: 5-fluorouracil, GEM: Gemcitabine, CAP: Capecitabine, ORR: Overall response rate, DCR: Disease Control rate

**Figure 1:** (a) This Kaplan–Meier survival curve summarises the progression-free survival according to the extent of disease. (b) This Kaplan–Meier survival curve depicts the overall survival according to the extent of disease (LAPC: Locally advanced pancreatic cancer, MPC: Metastatic pancreatic cancer)
week, and logistic issues might affect the choice of chemotherapy. None of the subjects in the present study had GEM and nanoparticle albumin-bound paclitaxel (Nab-Paclitaxel) as it was not available in the hospital. The choice of chemotherapy has a significant bearing on the outcome, especially in good performance status, which needs to be looked at in future studies.

The median PFS in this study was 32 weeks, and OS was 54 weeks. However, after breaking down into the subjects with LAPC, the median PFS was clinically significant, 39 weeks and OS of 66 weeks. Median-free survival in MPC was 25 weeks, and OS was 49 weeks, consistent with other studies.\[19,20\]

The tumour control rate was 48% (11 out of 23 subjects) in the FOLFIRINOX group compared to the 22% (12 out of 56 subjects) in the GEM group during the same time. PFS was significantly higher in the LAPC group than MPC. There might be multiple reasons for this, including better performance status, less dose reduction, choice of treatment (more 5FU-based chemotherapy in LAPC than in MPC) and perhaps the biology of cancer itself. More subjects were treated with 5FU-based chemotherapy in LAPC $n = 16$, 70%; MPC $n = 7$, 30%. These results were similar to those reported in previous Phase III trials of chemotherapy in advanced pancreatic cancer.\[13\]

Unfortunately, the OS in this study was not different between the two groups. This is intriguing and could be explained by the smaller size of the cohort and warrant further studies. The ORR is compatible with the published international literature with more responses in FOLFIRINOX than GEM or CAP alone.\[20\]

For LAPC, the resection rates vary in different studies. In a systemic review of nearly 13 trials using FOLFIRINOX as neoadjuvant chemotherapy, the resection rates were reported from 0 to 43%, and R0 resection was reported in 74%.\[21\] Most of the studies from the South Asia region have looked at the surgical outcome in LAPC, and the data are very sparse on the long-term survival outcome of the patient who received any chemotherapy.\[22\] In this study, only three subjects out of 47 (6%) were deemed resectable, and out of three, two had R1 resection. These subjects unfortunately relapsed within 3 months, and all of them died within 12 months. All of these subjects were treated with FOLFIRINOX. This is again interesting as it seems that the outcome of these subjects was not much different from the one who did not have surgery. This is difficult to say with certainty as the number of subjects was small to make any robust conclusion.

This study had few limitations. First, this was a retrospective analysis, therefore liable to have
selection bias and incomplete data collection, but as the electronic patient record was used to document and retrieve data, therefore, this should not be a case. Due to the small sample size, the outcome of subjects with LAPC who had curative surgery after chemotherapy could not be inferred robustly and need further studies with more significant numbers. Another limitation was the small number of subjects, which makes the analysis less robust. This is because the metastatic pancreatic subjects presenting to the hospital were not accepted for treatment as per the hospital policy. Therefore, only subjects who had LAPC or metastatic cancer not evident on the initial investigations (ultrasound liver and chest radiograph) were accepted, who later showed evidence of metastases on the subsequent imaging or during follow-up.

FOLFIRINOX emerged as the most successful chemotherapy regimen, albeit with dose reductions and toxicities. The subjects with both LAPC and MPC fared better on it. Modified FOLFIRINOX could be easily used in the Southeast Asian population with a similar outcome as shown in Western populations.

References

1. di Marco M, di Cicilia R, Macchini M, Nobili E, Vecchiarella S, Brandi G, et al. Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? Oncol Rep 2010;23:1183-92.
2. Louvet C, Labianca R, Hammel P, Lledo G, Zampino M, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
3. Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ 2012;344:e2476.
4. Furuse J, Nagashima F. Current status and future direction of chemotherapy for pancreatic cancer. Chin Clin Oncol 2013;2:6.
5. Ducrœux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v56-68.
6. Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O’Reilly EM, et al. Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 2016;34:2784-96.
7. Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer—a case report and review. BMC Cancer 2016;16:786.
8. Rombouts S, Mungroop T, Heilmann M, van Laarhoven H, Busch O, Molenaar I, et al. FOLFIRINOX in locally advanced and metastatic pancreatic cancer: A single centre cohort study. J Cancer 2016;7:1861-66.
9. Burris H 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with Gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-13.
10. Kindler H, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with Gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol 2010;28:3617-22.
11. Philip PA, Benedetti J, Corless CL, Wang R, O’Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605-10.
12. Moore MJ, Goldstein D, Hamm J, Figer AJ, Hecht JR, Gallinger S, et al. Erlotinib plus Gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer: A Phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007;25:1960-6.
13. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
14. Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a groupe tumours digestive of the federation nationale des centres de lutte contre le cancer study. J Clin Oncol 2005;23:1228-36.
15. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012;13:497-501.
16. Ducrœux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26:v56-68.
17. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L,
Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (Version 1.1). Eur J Cancer 2009;45:228-47.
18. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
19. Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, et al. FOLFIRINOX in locally advanced pancreatic cancer: The massachusetts general hospital cancer center experience. Oncologist 2013;18:543.
20. Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: Results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol 2015;22:295-301.
21. Schmoll HJ, Haustermans K, Price TJ, Nordlinger B, Hofheinz R, Daisne JF, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. Am Soc Clin Oncol 2014;27:VI154.
22. Zahir MN, Jabbar AA. Metastatic pancreatic carcinoma and experience with FOLFIRINOX-a cross sectional analysis from a developing country. Asian Pac J Cancer Prev 2015;16:6001-6.

Authorship Contributions
Conceived and designed the analysis: SY, SASK and UA, collected the data: SY, FA and SS, contributed data or analysis tools: SY, FA, SS and FB, performed the analysis: SY and FB, wrote the paper: SY, SASK and UA.